The role of radiotherapy in the overall treatment of melanoma

Clinics in Dermatology

Volumn 31, Issue 3, 2013, Pages 282-289

  Forschner, Andrea ^a   Heinrich, Vanessa ^a   Pflugfelder, Annette ^a   Meier, Friedegund ^a   Garbe, Claus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; MELPHALAN; VEMURAFENIB;

ABSENCE OF SIDE EFFECTS; ARTICLE; BONE METASTASIS; BRAIN EDEMA; BRAIN METASTASIS; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PRACTICE; COGNITIVE DEFECT; DESMOPLASTIC MELANOMA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GAMMA KNIFE RADIOSURGERY; HAIR LOSS; HUMAN; HYPERTHERMIA; IN-TRANSIT METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; MALIGNANT LENTIGO; MELANOMA; MUCOSAL MELANOMA; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REGIONAL METASTASIS; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME; UVEA MELANOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; INDOLES; MELANOMA; RECURRENCE; SKIN NEOPLASMS; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84876707877     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.08.009     Document Type: Article

References (74)

1. Fertil B., Malaise E.P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 1985, 11:1699-1707.
2. Doss L.L., Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys 1982, 8:1131-1134.
3. Bentzen S.M., Overgaard J., Thames H.D., et al. Clinical radiobiology of malignant melanoma. Radiother Oncol 1989, 16:169-182.
4. Overgaard J., von der Maase H., Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys 1985, 11:1837-1839.
5. Emami B., Perez C.A., Konefal J., et al. Thermoradiotherapy of malignant melanoma. Int J Hyperthermia 1988, 4:373-381.
6. Overgaard J., Gonzalez Gonzalez D., et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996, 12:3-20.
7. Million R.R., Cassisi N.J. Management of head and neck cancer: a multidisciplinary approach 1984, Lippincott, Philadelphia.
8. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
9. Sosman J.A., Kim K.B., Schuchter L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
10. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
11. Marsden J.R., Newton-Bishop J.A., Burrows L., et al. Revised U.K. Guidelines for the management of Cutaneous Melanoma 2010. Br J Dermatol 2010, 163:238-256.
12. National Comprehensive Cancer Network NCC Clinical Practice Guidelines in Oncology: Melanoma Available from:, Accessed June 22, 2011. http://www.24hmb.com/UpLoad/Editor/2010/1/4/2010010471289937.pdf.
13. Testori A., Rutkowski P., Marsden J., et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 2009, 20:22-29.
14. Seegenschmiedt M.H., Keilholz L., Altendorf-Hofmann A., et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumour response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999, 44:607-618.
15. Stevens G., Thompson J.F., Firth I., et al. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000, 88:88-94.
16. Johanson C.R., Harwood A.R., Cummings B.J., et al. 0-7-21 radiotherapy in nodular melanoma. Cancer 1983, 51:226-232.
17. Farshad A., Burg G., Panizzon R., et al. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002, 146:1042-1046.
18. Harwood A.R. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radiat Oncol Biol Phys 1983, 9:1019-1021.
19. Tsang R.W., Liu F.F., Wells W., et al. Lenitgo maligna of head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994, 130:1008-1012.
20. Weinzweig N., Tuthill R.J., Yetman R.J. Desmoplastic malignant melanoma: a clinicohistopathologic review. Plast Reconstr Surg (1946) 1995, 95:548-555.
21. Egbert B., Kempson R., Sagebiel R. Desmoplasticmalignantmelanoma. A clinicohistopathologic study of 25 cases. Cancer 1988, 62:2033-2041.
22. Vongtama R., Safa A., Gallardo D., et al. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck 2003, 25:423-428.
23. Foote M.C., Burmeister B., Burmeister E., et al. Desmoplastic melanoma: the role of radiotherapy in improving local control. ANZ J Surg 2008, 78:273-276.
24. Arora A., Lowe L., Su L., et al. Wide excision without radiation for desmoplastic melanoma. Cancer 2005, 104:1462-1467.
25. Chang A.E., Karnell L.H., Menck H.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998, 83:1664-1678.
26. Rogo K.O., Andersson R., Edbom G., et al. Conservative surgery for vulvovaginal melanoma. Eur J Gynaecol Oncol 1991, 12:113-119.
27. Douglas C.M., Malik T., Swindell R., et al. Mucosal melanoma of the head and neck: radiotherapy or surgery?. J Otolaryngol Head Neck Surg 2010, 39:385-392.
28. Batsakis J.G., Suarez P. Mucosal melanomas: a review. Adv Anat Pathol 2000, 7:167-180.
29. Kingdom T.T., Kaplan M.J. Mucosal melanoma of the nasal cavity and paranasal sinuses. Head Neck 1995, 17:184-189.
30. Owens J.M., Roberts D.B., Myers J.N. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 2003, 129:864-868.
31. Ragnarsson-Olding B.K., Nilsson B.R., Kanter-Lewensohn L.R., et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer 1999, 86:1285-1293.
32. Brady M.S., Kavolius J.P., Quan S.H. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum 1995, 38:146-151.
33. Ballo M.T., Gershenwald J.E., Zagars G.K., et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 2002, 20:4555-4558.
34. Trotti A., Peters L.J. Role of radiotherapy in the primary management of mucosal melanoma of the head and neck. Semin Surg Oncol 1993, 9:246-250.
35. Temam S., Mamelle G., Marandas P., et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer 2005, 103:313-319.
36. Herlyn M., Nathanson K.L. Taking the guesswork out of uveal melanoma. N Engl J Med 2010, 363:2256-2257.
37. Diener-West M., Earle J.D., Fine S.L., et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001, 119:969-982.
38. Hungerford J.L. Current trends in the treatment of ocular melanoma by radiotherapy. Clin Experiment Ophthalmol 2003, 31:8-13.
39. Höcht S., Bechrakis N.E., Nausner M., et al. Proton therapy of uveal melanomas in Berlin. 5 years of experience at the Hahn-Meitner Institute. Strahlenther Onkol 2004, 180:419-424.
40. Dieckmann K., Georg D., Zehetmayer M., et al. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiother Oncol 2003, 67:199-206.
41. Burmeister B.H., Smithers B.M., Poulsen M., et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995, 19:369-371.
42. Calabro A., Singletary S.E., Balch C.M. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989, 124:1051-1055.
43. Lee R.J., Gibbs J.F., Proulx G.M., et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000, 46:467-474.
44. Fuhrmann D., Lippold A., Borrosch F., et al. Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas?. Br J Dermatol 2001, 144:66-70.
45. Moncrieff M.D., Martin R., O'Brien C.J., et al. Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients?. Ann Surg Oncol 2008, 15:3022-3027.
46. Henderson M.A., Burmeister B., Thompson J.F., et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: results of an intergroup randomized trial. J Clin Oncol 2009, 827:18s. (suppl; abstr LBA9084).
47. Agrawal S., Kane J.M., Guadagnolo B.A., et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009, 115:5836-5844.
48. Corry J., Smith J.G., Bishop M., et al. Nodal radiation therapy for metastatic melanoma. Int J Radiat Oncol Biol Phys 1999, 44:1065-1069.
49. Radny P., Caroli U.M., Bauer J., et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003, 89:1620-1626.
50. Lindner P., Doubrovsky A., Kam P.C., et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002, 9:127-136.
51. Engin K., Tupchong L., Waterman F.M., et al. Hyperthermia and radiation in advanced malignant melanoma. Int J Radiat Oncol Biol Phys 1993, 25:87-94.
52. Overgaard J. Gonzalez Gonzalez D, Hulshof MC, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. 1996. Int J Hyperthermia 2009, 25:323-334.
53. Staudt M., Lasithiotakis K., Leiter U., et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010, 102:1213-1218.
54. Eigentler T.K., Figl A., Krex D., et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011, 117:1697-1703.
55. Sampson J.H., Carter J.H., Friedman A.H., et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998, 88:11-20.
56. Wroński M., Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 2000, 93:9-18.
57. Isokangas O.P., Muhonen T., Kajanti M., et al. Radiation therapy of intracranial malignant melanoma. Radiother Oncol 1996, 38:139-144.
58. Brown P.D., Brown C.A., Pollock B.E., et al. Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery 2002, 51:656-665.
59. McWilliams R.R., Brown P.D., Buckner J.C., et al. Treatment of brain metastases from melanoma. Mayo Clin Proc 2003, 78:1529-1536.
60. Yu C., Chen J.C., Apuzzo M.L., et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 2002, 52:1277-1287.
61. Mori Y., Kondziolka D., Flickinger J.C., et al. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 1998, 42:581-589.
62. Gaudy-Marqueste C., Regis J.M., Muracciole X., et al. Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 2006, 65:809-816.
63. Grob J.J., Regis J., Laurans R., et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancérologie Cutanée. Eur J Cancer 1998, 34:1187-1192.
64. Zygogianni A., Kyrgias G., Kouvaris J., et al. Melanoma: the radiotherapeutic point of view; review of the current literature. Rev Recent Clin Trials 2011, 6:127-133.
65. Rate W.R., Solin L.J., Turrisi A.T. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys 1988, 15:859-864.
66. Kirova Y.M., Chen J., Rabarijaona L.I., et al. Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 1999, 9:611-613.
67. Timmerman R., Paulus R., Galvin J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076.
68. Shibamoto Y., Hashizume C., Baba F., et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: a multicenter study. Cancer 2012, 118:2078-2084.
69. Stinauer M.A., Kavanagh B.D., Schefter T.E., et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol 2011, 6:34.
70. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
71. Ugurel S., Thirumaran R.K., Bloethner S., et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One 2007, 21:e236.
72. Brose M.S., Volpe P., Feldman M., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62:6997-7000.
73. Grana T.M., Rusyn E.V., Zhou H., et al. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 2002, 62:4142-4150.
74. Sambade M.J., Peters E.C., Thomas N.E., et al. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 2011, 98:394-399.